Sugi Predict

Sugi Predict / Compounds / SCHEMBL731556

SCHEMBL731556

SCHEMBL731556

O=c1ccc2cccc(Br)c2[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 4/20 1.00
▸ CA9 Q16790 4/20 1.00
▸ CA1 P00915 1/20 0.47
▸ CA3 P07451 1/20 0.47
▸ CA4 P22748 1/20 0.47
▸ CA6 P23280 1/20 0.47
▸ CA5A P35218 1/20 0.47
▸ CA7 P43166 1/20 0.47
▸ CA13 Q8N1Q1 1/20 0.47
▸ CA14 Q9ULX7 1/20 0.47
▸ CA5B Q9Y2D0 1/20 0.47
▸ NOS1 P29475 1/20 0.42
▸ HCAR1 Q9BXC0 5/20 0.38
▸ HRH4 Q9H3N8 1/20 0.38
▸ ENPP3 O14638 1/20 0.38
▸ ENPP1 P22413 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ BACE1 P56817 1/20 0.34
▸ AKR1B1 P15121 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19713068 0.86 CA12 (0.76) CA12CA9CA1CA3CA4
SCHEMBL16050842 0.77 CA12 (0.62) CA12CA9CA1CA3CA4
SCHEMBL28682189 0.75 CA12 (0.60) CA12CA9NOS1HRH4ENPP3
SCHEMBL30063823 0.75 CA12 (0.60) CA12CA9CA1CA3CA4
SCHEMBL433883 0.75 CA12 (0.60) CA12CA9CA1CA3CA4
SCHEMBL3137037 0.75 CA12 (1.00) CA12CA9CA1CA3CA4
SCHEMBL29385308 0.75 CA12 (0.60) CA12CA9CA1CA3CA4
SCHEMBL3224071 0.75 CA12 (0.60) CA12CA9CA1CA3CA4
SCHEMBL4178782 0.75 CA12 (1.00) CA12CA9CA1CA3CA4
SCHEMBL19751458 0.75 CA12 (0.60) CA12CA9CA1CA3CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4524135-A1 KINESIN KIF18A INHIBITOR AND USE THEREOF Shanghai Apeiron Therapeutics Company Limited (CN) 2025-03-19 — — EP disclosed
CN-119212988-A Kinesin KIF18A inhibitor and application thereof 上海湃隆生物科技有限公司 2024-12-27 — — CN disclosed
EP-3956033-B1 BICYCLIC COMPOUNDS VIVACE THERAPEUTICS INC (US) 2024-12-11 — — EP disclosed
US-12103902-B2 Bicyclic compounds VIVACE THERAPEUTICS, INC. (US) 2024-10-01 — — US disclosed
WO-2024188287-A1 BRM INHIBITOR AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 贝达药业股份有限公司 2024-09-19 — — WO disclosed
CN-114072207-B Bicyclic compounds 维瓦斯治疗公司 2024-03-29 — — CN disclosed
US-11859032-B2 Ethylene-a-olefin-diene elastomers and methods of making them EXXONMOBIL CHEMICAL PATENTS INC. (US) 2024-01-02 — — US disclosed
WO-2023217230-A1 KINESIN KIF18A INHIBITOR AND USE THEREOF 上海湃隆生物科技有限公司 2023-11-16 — — WO disclosed
WO-2023201012-A1 IKZF2 DEGRADERS AND USES THEREOF REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2023-10-19 — — WO disclosed
US-20220298102-A1 BICYCLIC COMPOUNDS VIVACE THERAPEUTICS, INC. 2022-09-22 — — US disclosed
US-20080221110-A1 Compounds GLAXO GROUP LIMITED (GB) 2008-09-11 — — US disclosed
WO-2008099000-A2 SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-08-21 — — WO disclosed
WO-2008099000-A2 SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-08-21 — — WO disclosed
EP-1954697-A2 PERI CONDENSED TRICYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS GLAXO GROUP LIMITED (GB) 2008-08-13 — — EP disclosed
WO-2007081597-A2 PERI CONDENSED TRICYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS GLAXO GROUP LIMITED (GB) 2007-07-19 — — WO disclosed
US-6821967-B2 AMINES SUCH AS 9-(4-(4-(BENZOTHIAZOL-2-YL)-PIPERAZIN-1-YL)-BUTYL)-9H-FLUORENE-9-CARBOXYLIC ACID (2,2,2-TRIFLUOROETHYL) AMIDE, USED AS MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN ANTAGONISTS, TO PREVENT ATHEROSCLEROSIS OR HYPERLIPEMIA BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-11-23 — — US disclosed
US-20030166637-A1 Substituted piperazine derivatives, the preparation thereofand their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-09-04 — — US disclosed
EP-1255736-A2 SUBSTITUTED PIPERAZINE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) Boehringer Ingelheim Pharma KG (DE) 2002-11-13 — — EP disclosed
WO-2001047898-A2 SUBSTITUTED PIPERAZINE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) BOEHRINGER INGELHEIM PHARMA KG (DE) 2001-07-05 — — WO disclosed
US-4349554-A Method of using carbostyril derivatives as plant fungicides SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1982-09-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166637-A1 Substituted piperazine derivatives, the preparation thereofand their use as medicaments MTTP, CETP, CPT1A CA12 4881/4885CA9 4880/4885CA1 4848/4885
US-20220298102-A1 BICYCLIC COMPOUNDS YAP1, TEAD2, TEAD3 CA12 4576/4885CA9 3806/4885CA1 4630/4885
US-12103902-B2 Bicyclic compounds YAP1, TEAD2, TEAD3 CA12 4686/4885CA9 4096/4885CA1 4809/4885
US-20080221110-A1 Compounds NRDC, NISCH, MRPL21 CA12 2476/4885CA9 1182/4885CA1 4162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.